{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:04:28Z","timestamp":1792598668748,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T00:00:00Z","timestamp":1632096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nivolumab is an anti-programmed cell death protein 1 antibody, typically used as cancer immunotherapy agent. Despite multiple clinical benefits it might cause autoimmune-related side-effects, often involving the endocrine system. To our knowledge, this is the first case of nivolumab-induced hypophysitis manifesting several months after treatment discontinuation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We, herein, report a 53-year-old patient with hypophysitis and isolated adrenocorticotropic hormone deficiency, who presented with recurring syncopal episodes and persistent mild hyponatremia. The performed challenged tests were consistent with secondary adrenal insufficiency, while responses of other anterior pituitary hormones were preserved. Magnetic resonance imaging revealed thickened pituitary stalk, consistent with hypophysitis. The patient\u2019s condition gradually improved after administration of hydrocortisone, with normalization of sodium and glucose-levels. The related literature is discussed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We conclude that even after discontinuation of nivolumab, isolated adrenal insufficiency can occur. Therefore, in case of administration of such agents, clinical assessment, and routine monitoring of blood pressure, sodium-, glucose-levels, pituitary hormones as well as magnetic resonance imaging are needed to identify such conditions and prevent an adrenal crisis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-021-00854-y","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T15:03:05Z","timestamp":1632150185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Sofia","family":"Antoniou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Bazazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"R\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-874X","authenticated-orcid":false,"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,20]]},"reference":[{"key":"854_CR1","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1210\/jc.2010-2970","volume":"96","author":"P Leporati","year":"2011","unstructured":"Leporati P, Landek-Salgado MA, Lupi I, et al. IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab. 2011;96:1971\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"854_CR2","doi-asserted-by":"publisher","first-page":"R151","DOI":"10.1530\/EJE-17-0009","volume":"179","author":"MN Joshi","year":"2018","unstructured":"Joshi MN, Whitelaw BC, Carroll PV. Mechanisms in endocrinology: Hypophysitis: diagnosis and treatment. Eur J Endocrinol. 2018;179:R151-63.","journal-title":"Eur J Endocrinol"},{"key":"854_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary. 2016;19:82\u201392.","journal-title":"Pituitary"},{"key":"854_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/00042737-200606000-00019","volume":"18","author":"E Ridruejo","year":"2006","unstructured":"Ridruejo E, Christensen AF, Mando OG. Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin. Eur J Gastroenterol Hepatol. 2006;18:693\u20134.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"854_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3171\/jns.2006.105.2.309","volume":"105","author":"SI Moskowitz","year":"2006","unstructured":"Moskowitz SI, Hamrahian A, Prayson RA, et al. Concurrent lymphocytic hypophysitis and pituitary adenoma. Case report and review of the literature. J Neurosurg. 2006;105:309\u201314.","journal-title":"J Neurosurg"},{"key":"854_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1053\/j.seminoncol.2018.09.002","volume":"45","author":"C Solinas","year":"2018","unstructured":"Solinas C, Porcu M, De Silva P, et al. Cancer immunotherapy-associated hypophysitis. Semin Oncol. 2018;45:181\u20136.","journal-title":"Semin Oncol"},{"key":"854_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","volume":"1","author":"J Larkin","year":"2015","unstructured":"Larkin J, Lao CD, Urba WJ, et al. Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol. 2015;1:433\u201340.","journal-title":"JAMA Oncol"},{"key":"854_CR8","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371\u201381.","journal-title":"Endocr Relat Cancer"},{"key":"854_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1507\/endocrj.EJ16-0161","volume":"63","author":"Y Okano","year":"2016","unstructured":"Okano Y, Satoh T, Horiguchi K, et al. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. Endocr J. 2016;63:905\u201312.","journal-title":"Endocr J"},{"key":"854_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12902-019-0335-x","volume":"19","author":"A Takeno","year":"2019","unstructured":"Takeno A, Yamamoto M, Morita M, et al. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report. BMC Endocr Disord. 2019;19:25.","journal-title":"BMC Endocr Disord"},{"key":"854_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.","journal-title":"J Immunother Cancer"},{"key":"854_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","volume":"44","author":"P Fessas","year":"2017","unstructured":"Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017;44:136\u201340.","journal-title":"Semin Oncol"},{"key":"854_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/CCO.0000000000000293","volume":"28","author":"F Torino","year":"2016","unstructured":"Torino F, Corsello SM, Salvatori R. Endocrinological side-effects of immune checkpoint inhibitors. Curr Opin Oncol. 2016;28:278\u201387.","journal-title":"Curr Opin Oncol"},{"key":"854_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330.","journal-title":"Lancet Oncol"},{"key":"854_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EJE-19-0238","volume":"181","author":"A Faje","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L, et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019;181:211\u20139.","journal-title":"Eur J Endocrinol"},{"key":"854_CR16","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6:230ra45.","journal-title":"Sci Transl Med"},{"issue":"9","key":"854_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1158\/2326-6066.CIR-14-0040","volume":"2","author":"C Wang","year":"2014","unstructured":"Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846\u201356.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"854_CR18","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.3390\/jcm9103280","volume":"9","author":"M Levy","year":"2020","unstructured":"Levy M, Abeillon J, Dalle S, et al. Anti-PD1 and Anti-PDL1-Induced Hypophysitis: a cohort study of 17 patients with longitudinal follow-up. J Clin Med. 2020;9(10):3280.","journal-title":"J Clin Med"},{"key":"854_CR19","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.2217\/fon-2019-0101","volume":"15","author":"F Castillero","year":"2019","unstructured":"Castillero F, Castillo-Fern\u00e1ndez O, Jim\u00e9nez-Jim\u00e9nez G, et al. Cancer immunotherapy-associated hypophysitis. Future Oncol. 2019;15:3159\u201369.","journal-title":"Future Oncol"},{"key":"854_CR20","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1210\/jc.2012-4171","volume":"98","author":"AF Turcu","year":"2013","unstructured":"Turcu AF, Erickson BJ, Lin E, et al. Pituitary stalk lesions: the Mayo Clinic experience. J Clin Endocrinol Metab. 2013;98:1812\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"854_CR21","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3174\/ajnr.A1623","volume":"30","author":"KJ Carpenter","year":"2009","unstructured":"Carpenter KJ, Murtagh RD, Lilienfeld H, et al. Ipilimumab-induced hypophysitis: MR imaging findings. Am J Neuroradiol. 2009;30:1751\u20133.","journal-title":"Am J Neuroradiol"},{"key":"854_CR22","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99:4078\u201385.","journal-title":"J Clin Endocrinol Metab"},{"key":"854_CR23","unstructured":"Prete A, Salvatori R. Hypophysitis. In: Feingold KR, Anawalt B, Boyce A, et al, editors. Endotext. South Dartmouth:MDText.com, Inc.\u00a02000\u00a0PMID: 30160871."},{"key":"854_CR24","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1210\/jc.2015-2152","volume":"100","author":"J Honegger","year":"2015","unstructured":"Honegger J, Schlaffer S, Menzel C, et al. Diagnosis of primary hypophysitis in Germany. J Clin Endocrinol Metab. 2015;100:3841\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"854_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01141-8","author":"P Iglesias","year":"2021","unstructured":"Iglesias P, S\u00e1nchez JC, D\u00edez JJ. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Pituitary. 2021. https:\/\/doi.org\/10.1007\/s11102-021-01141-8.","journal-title":"Pituitary"},{"key":"854_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1530\/EJE-17-0810","volume":"178","author":"ES Scott","year":"2018","unstructured":"Scott ES, Long GV, Guminski A, et al. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol. 2018;178:175\u201382.","journal-title":"Eur J Endocrinol"},{"key":"854_CR27","first-page":"e245","volume":"34","author":"I Lupi","year":"2011","unstructured":"Lupi I, Manetti L, Raffaelli V, et al. Diagnosis and treatment of autoimmune hypophysitis: a short review. J Endocrinol Invest. 2011;34:e245-52.","journal-title":"J Endocrinol Invest"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-021-00854-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-021-00854-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T15:09:24Z","timestamp":1632150564000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-021-00854-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,20]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["854"],"URL":"https:\/\/doi.org\/10.1186\/s12902-021-00854-y","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,20]]},"assertion":[{"value":"29 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}